Cytokinetics EVP sells 3,500 shares after option exercise

CYTOKINETICS INC EVP Research & Development Fady Ibraham Malik reported an option exercise paired with a share sale.

Rhea-AI Filing Summary

CYTOKINETICS INC EVP Research & Development Fady Ibraham Malik reported an option exercise paired with a share sale. On June 9, 2026, he exercised options to acquire 3,500 shares of common stock at $7.80 per share and sold 3,500 shares in an open-market transaction at $67.98 per share.

Following these transactions, he directly owned 153,902 shares of common stock and held 44,386 non-qualified stock options. The activity reflects converting a portion of stock options into shares and immediately selling an equivalent number of shares for cash while retaining a substantial remaining equity position.

Insider Trade Summary 10b5-1

Exercise and Sale: 3,500 shares ($211K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Malik Fady Ibraham

Role EVP Research & Development

Sold 3,500 shs ($238K)

Approx. gross sale proceeds $238K

Approx. exercise cost $27K

Approx. pre-tax spread $211K

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (Right to Buy)	3,500	$0.00	$0.00
Exercise	Common Stock	3,500	$7.80	$27K
Sale	Common Stock	3,500	$67.98	$238K

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 44,386 contracts (Direct); Common Stock — 153,902 shares (Direct)

Key Figures

Shares sold: 3,500 shares Sale price: $67.98 per share Options exercised: 3,500 options +3 more

6 metrics

Shares sold 3,500 shares Open-market sale of common stock at $67.98 per share

Sale price $67.98 per share Price for 3,500 common shares sold in open market

Options exercised 3,500 options Non-qualified stock options exercised into common stock

Exercise price $7.80 per share Exercise price for non-qualified stock options

Shares owned after 153,902 shares Direct common stock holdings following transactions

Options remaining 44,386 options Non-qualified stock options outstanding after exercise

Key Terms

open-market sale, Non-Qualified Stock Option (Right to Buy), derivative exercise/conversion

3 terms

open-market sale financial

"3,500 shares of common stock were disposed of in an open-market sale at $67.98 per share."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Non-Qualified Stock Option (Right to Buy) financial

"The insider exercised 3,500 Non-Qualified Stock Option (Right to Buy) awards with a $7.80 exercise price."

derivative exercise/conversion financial

"The transaction was reported as a derivative exercise/conversion of options into common stock."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CYTOKINETICS (CYTK) report for EVP Fady Malik?

CYTOKINETICS (CYTK) reported that EVP Research & Development Fady Ibraham Malik exercised stock options and sold shares. He exercised 3,500 options and sold 3,500 common shares in an open-market transaction, pairing a derivative exercise with an immediate sale the same day.

How many CYTOKINETICS (CYTK) shares did the EVP sell and at what price?

The EVP sold 3,500 shares of CYTOKINETICS common stock at $67.98 per share. This open-market sale matched the number of options he exercised, effectively converting option value into cash while maintaining a significant remaining shareholding in the company.

What stock options did the CYTOKINETICS (CYTK) EVP exercise in this Form 4?

He exercised 3,500 non-qualified stock options with a $7.80 exercise price into common shares. These options were originally granted with an expiration date in 2028, and after the exercise he still held 44,386 options for CYTOKINETICS common stock.

How many CYTOKINETICS (CYTK) shares does the EVP hold after these transactions?

After the reported transactions, the EVP directly owned 153,902 shares of CYTOKINETICS common stock. This post-transaction balance shows that the 3,500-share sale represented only a portion of his overall equity position in the company.

Does the CYTOKINETICS (CYTK) Form 4 show a routine exercise-and-sell pattern?

Yes. The filing shows a classic exercise-and-sell pattern, with 3,500 options exercised at $7.80 and the same 3,500 shares sold at $67.98. This sequence converts options into cash while leaving the executive with substantial remaining shares and options in CYTOKINETICS.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/09/2026 - 05:40 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malik Fady Ibraham

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP Research & Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/09/2026		M		3,500	A	$7.8	157,402	D
Common Stock	06/09/2026		S		3,500	D	$67.98	153,902	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (Right to Buy)	$7.8	06/09/2026		M			3,500	03/27/2018	02/27/2028	Common Stock	3,500	$0	44,386	D

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Dr. Malik	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)